Rare Disorders NZ has made a submission in response to Pharmac’s proposal to fund Emicizumab for severe Haemophillia A.
Rare Disorders NZ supports the proposal to widen access to emicizumab, brand name Hemlibra, for the treatment of severe Haemophilia A without FVIII inhibitors, subject to eligibility criteria.
As stated by the proposal, this would mean that any person with severe Haemophilia A, defined as endogenous factor VIII activity less than or equal to 2%, would have access to funded emicizumab, regardless of FVIII inhibitor titre.
Rare Disorders NZ welcomes this huge step towards meeting internationally recognised standards of care for people with severe Haemophillia A. We request the proposal is approved with no further delay.